New! View global litigation for patent families

US4879062A - Preparation of a gel having gas transporting capability - Google Patents

Preparation of a gel having gas transporting capability Download PDF

Info

Publication number
US4879062A
US4879062A US06777798 US77779885A US4879062A US 4879062 A US4879062 A US 4879062A US 06777798 US06777798 US 06777798 US 77779885 A US77779885 A US 77779885A US 4879062 A US4879062 A US 4879062A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
gel
liquid
water
emulsion
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US06777798
Inventor
Robert E. Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alliance Pharmaceutical Corp
Original Assignee
Adamantech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026Blood substitute; Oxygen transporting formulations; Plasma extender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/02Cosmetics or similar toilet preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/042Gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/19Cosmetics or similar toilet preparations characterised by the composition containing inorganic ingredients
    • A61K8/22Peroxides; Oxygen; Ozone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/69Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing fluorine
    • A61K8/70Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0014Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/02Making solutions, dispersions or lattices by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03Making solutions, dispersions or lattices by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; MISCELLANEOUS COMPOSITIONS; MISCELLANEOUS APPLICATIONS OF MATERIALS
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00Materials not provided for elsewhere
    • C09K3/30Materials not provided for elsewhere for aerosols
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G
    • C08J2383/00Characterised by the use of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen, or carbon only; Derivatives of such polymers
    • C08J2383/04Polysiloxanes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/944Gel
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/969Ointment or salve base

Abstract

An inert, water-immiscible inert organic liquid having gas transport properties, water and a suitable emulsifying agent are formed into a stable gel by emulsifying a mixture of the same, concentrating the emulsion to form a gel phase and a liquid phase and separating the two phases. The resulting gel can be used as an ointment or cosmetic for skin irritations or wounds, or as a coating in industrial applications where extended contact of a surface with a gas, such as oxygen, is desired. Fluorocarbons or low viscosity silicone oils are suitable organic liquid components of the gels.

Description

RELATED APPLICATION

This application is a continuation of Ser. No. 313,124, filed Oct. 20, 1981 (now U.S. Pat. No. 4,569,784), which in turn is a continuation-in-part of Ser. No. 209,238 filed Nov. 17, 1980 and abandoned as of the filing date accorded this application.

BACKGROUND OF THE INVENTION

This invention relates to a process for preparing a gel composition based on an inert organic liquid having gas transporting capability. The invention also relates to the resulting gel composition, which gel has a variety of medical, cosmetic, industrial and other uses.

Many inert organic liquids are known which have gas transporting capabilities, that is, have high solubility for gases such as oxygen, nitrogen, carbon dioxide, the inert gases, and mixtures of gases including air. Among the many classes of inert organic liquids having such properties are water immiscible, liquid fluorocarbons and low viscosity silicone oils. These classes of liquids are described in U.S. Pat. No. 3,850,753 issued Nov. 26, 1974 to Chibata et al for the culturing of aerobic microorganisms. However, the patent does not mention emulsions or gel formulation therewith.

Other perfluorocarbons, emulsions thereof and their properties are described in the following U.S. Pat. Nos.: 4,220,606, R. E. Moore, Sept. 2, 1980; 4,143,079, R. E. Moore, Mar. 6, 1979; 4,105,798, R. E. Moore et al., Aug. 8, 1978; 4,041,086, Moore et al., Aug. 9, 1977; 3,911,138, L. C. Clark, Jr., Oct. 7, 1975; 3,962,439, K. Yokoyama et al., June 8, 1976; 3,993,581, K. Yokoyama et al., Nov. 23, 1976; 4,187,252, R. J. Lagow et al., Feb. 5, 1980; 4,110,474, R. J. Lagow et al., Aug. 29, 1978; and 3,641,167, Moore et al., Feb. 8, 1972. In U.S. application Ser. No. 52,041 filed June 25, 1979, (now abandoned), by David C. White, superseded by Ser. No. 228,642 filed Jan. 26, 1981 (now U.S. Pat. No. 4,366,169), a method of treating wounds, such as a burn, is disclosed wherein the burn is contacted with a liquid perfluorocarbon, directly or supported on a sponge, or in the form of a foam, spray or gel. There is no disclosure in the White application of any specific gel composition or of any process for preparing a gel composition.

The information contained in the aforementioned patents is incorporated herein by reference.

Techniques are known for separating various particulate materials from aqueous media in which they are formed or treated. For example, U.S. Pat. No. 2,107,839 describes isolation in dry powder form of the therapeutic agent derived from the natural latex of the Lactuca plant, by allowing the emulsion to break by standing, and then filtering or centrifuging to separate the aqueous solution containing the active constituent.

Further, a variety of gels are known which are produced from aqueous suspensions by precipitation, decantation, filtration (including membrane filtration) and centrifugation. The products are commonly isolated as dry materials and are called "gels" apparently because they revert to a semi-solid, somewhat plastic or swollen state upon contact with water. They exhibit high porosity and are used for a variety of purposes, depending on their origin, porosity and swellability. Among such materials are the gelatin-carboxymethyl cellulose complexes of U.S. Pat. No. 2,824,092; the soybean proteinate hydrogels of U.S. Pat. No. 3,218,307; the gelatinous flocculent obtained by fermenting a natural polysaccharide and then centrifuging, as in U.S. Pat. No. 3,096,293; hydroxy-lower alkyl ethers of galactomannans produced as stable, dry hydrocolloids by filtration and centrifugation, as in U.S. Pat. No. 3,326,890; the dry, agarose gels of U.S. Pat. No. 3,527,712; and the silica gels produced as in U.S. Pat. Nos. 3,346,507 and 3,560,400.

None of these patents, however, teach or suggest concentration of an emulsion accompanied by formation of a gelatinous material, nor preparation of a gelatinous material containing an inert, water-immiscible organic liquid gas transporting agent.

SUMMARY OF THE INVENTION

In accordance with the present invention, it has now been found that a gel composition can be prepared by (a) combining an inert, water-immiscible organic liquid having gas transport capabilities, water, and a suitable emulsifying agent, emulsifying the combined materials, concentrating the emulsion to form a gel phase and a liquid phase, and separating the liquid from the gel. the resulting gel is a stable composition which can be used, for example, as an ointment, salve or unguent, in the treatment of skin irritations or wounds, or of any condition requiring a gas such as oxygen. Gas transporting agents in gel form have the advantage over emulsions of far greater gas transport capability per unit volume since a large proportion of the non-gas transporting material, i.e., the water, is removed as a consequence of the present invention.

DETAILED DESCRIPTION

The term "gel" as used herein means a semisolid, apparently homogeneous, substance that may be elastic and jelly-like (as gelatin) or more or less rigid. Contrary to the teachings of the patents set forth above, the "gels" of this invention are not reducible to dry, particulate, porous form, nor do they exhibit any appreciable degree of swelling upon contact with water. "Gel" therefore is used herein in the more general sense of a gelatinous or jelly-like character.

"Perfluorocarbon" as used herein refers to a substantially fluorinated or completely fluorinated material which is generally but not necessarily a liquid at ambient temperature and pressure and which has the ability to transport gases such as oxygen and carbon dioxide.

"Substantially flourinated" in this specification means that most of the hydrogen atoms of a compound have been replaced by fluorine atoms, such that further replacement does not substantially increase the gas transport capability of the material. It is believed that this level is reached when at least about 80-90% of the hydrogen atoms have been replaced by fluorine atoms. In the aforementioned U.S. Pat. Nos. 3,911,138 and 4,105,798, the ability to transport oxygen is related to the solubility of a gas such as oxygen in the materials. These patents suggest that the perfluorinated materials will absorb 10-100 cc of oxygen per 100 cc of material at 25° C. and 760 milliliters of mercury. However, it is preferred that at least 95% of the hydrogen atoms have been replaced, more preferably at least 98% and even more preferably, 100%.

Fluorinated materials suitable for use in this invention include those which are broadly described as cyclic perfluorohydrocarbons or derivatives thereof. Examples are chemically inert C9 -C18 polycyclic compounds such as bicyclononanes (e.g., bicyclo [3.3.1] nonane, 2,6-dimethyl-bicyclo [3.3.1] nonane or 3-methylbicyclo [3.3.1] nonane), adamantane, methyl and dimethyladamantane, ethyl and diethyladamantane, tetrahydrodicyclopentadiene, methyl and dimethylbicyclooctanes, ethylmethyladamantane, ethyldimethyladamantane, tetrahydrobinor-S, methyldiadamantane, triethyladamantane, trimethyldiadamantane, pinane, camphane, 1,4,6, 9-dimethanodecalin, bicyclo [4.3.2] undecane, bicyclo [5.3.0] decane and the like, or any mixtures thereof. Other examples include perfluorotributyl amine, perfluoro-2-butyltetrahydrofuran,

perfluoro-2-butylfuran, perfluoro-n-heptane, perfluoronaphthalene, perfluoro-1-methyl-naphthalene, perfluoro-n-methyl-morpholine and perfluoro-1-methyldecaline and perfluoroethers such as the 1,2,2,2-tetrafluoromethyl ether of perfluoro (2,5,8-trimethyl-3,6,9-trioxa-1-dodecanol).

Certain of the fluorine atoms of the foregoing materials may be substituted by other halogen atoms such as bromine. Included among these compounds, are, for example, monobrominated compounds such a 1-bromo-pentadecafluoro-4-isopropylcyclohexane, 1-bromotridecafluorohexane, 1-bromo-pentadecafluorooctane and 1-bromopentadecafluoro-3-isopropylcyclopentane, or dibrominated derivatives thereof.

Perfluorinated C8 or lower materials and up to C18 or higher materials, included partially brominated analogs thereof, as well as mixtures of various different perfluorocompounds can be used in this invention.

Those of the foregoing fluorinated compounds which are solid at ambient temperature can be dissolved in a suitable solvent or in other perfluorocarbons which are liquid at ambient temperatures, and the resulting mixture can be used to form the emulsion and gel of the invention. "Liquid" in this specification when describing the fluorocarbons therefore means either a fluorocarbon which is per se liquid at ambient temperatures or a solution of a solid fluorocarbon in a fluorocarbon solvent.

Silicone oils useful in this invention, such as those mentioned in U.S. Pat. No. 3,850,753, should have a viscosity of from about 0.65 to about 15 centipoise, such as the silicone oil "DC-200-1CD" manufactured by Dow Corning Corporation having a molecular weight of 316, specific gravity 0.85, and an oxygen solubility of 100 ml/100 ml. liquid at 25° C. Other silicone fluids available from the Dow-Corning Corporation having utility in this invention are generally described as "DC-200" fluids. Chemically, the silicone oils are polydimethyl siloxanes, and are also known as liquid methyl silicones. Similar silicone fluids are available from the General Electric Company.

In the first step of preparing the gels, the inert organic, gas transporting liquid is emulsified in water in the presence of an emulsifying agent. The emulsifying agent is selected such that when admixed with the water and the organic liquid, effective emulsification and stability of the gel will result. The emulsifying agent should be compatible with the organic liquid and have no adverse effect when the gel is applied, for example, to the human skin.

Although nonionic emulsifiers are preferred, because they are effective in hard or soft water and are not pH dependant, ionic emulsifiers can also be used, whether anionic, cationic or amphoteric.

Suitable nonionic emulsifiers include alkylphenoxypolyethoxyethanols having alkyl groups of about seven to eighteen carbon atoms and 1 to 60 or more oxyethylene units, such as heptylphenoxypolyethoxyethanols, octylphenoxypolyethoxyethanols, methyloctylphenoxypolyethoxyethanols, nonylphenoxypolyethoxye thanols, dodecylphenoxypolyethoxyethanols, and the like; polyethoxyethanol derivatives of methylene linked alkylphenols; sulfur-containing agents such as those made by condensing 1 to 60 or more moles of ethylene oxide with nonyl, dodecyl, tetradecyl, t-dodecyl, and the like mercaptans or with alkylthiophenols having alkyl groups of six to fifteen carbon atoms; ethylene oxide derivatives of long-chain carboxylic acids, such as lauric, myristic, palmitic, oleic, and the like or mixtures of acids such as are found in tall oil containing 1 to 60 oxyethylene units per molecule; analogous ethylene oxide condensates of long-chain alcohols, such as octyl, decyl, lauryl, or cetyl alcohols; ethylene oxide derivatives of etherified or esterified polyhydroxy compounds having a hydrophobic hydrocarbon chain, such as sorbitan monostearate containing 1 to 60 oxyethylene units; also, ethylene oxide condensates of long-chain or branched-chain amines, such as dodecylamine, hexadecylamine, and octadecylamine, containing 1 to 60 oxyethylene groups; and block copolymers of ethylene oxide and propylene oxide comprising a hydrophobic propylene oxide section combined with one or more hydrophilic ethylene oxide sections.

Examples of useful anionic emulsifiers include the ordinary soaps such as the alkali metal, ammonium and alkanolamine salts of fatty acids including sodium oleate, potassium palmitate, ammonium stearate, ethanolamine laurate, and the like, as well as rosin and dehydrated rosin acid soaps, and the synthetic saponaceous materials including the higher aliphatic sulfates and sulfonates such as sodium lauryl sulfate, sodium cetyl sulfate, the sodium salts of sulfonated paraffin oils, the sodium salts of dodecane-1-sulfonic acid, octadecane 1-sulfonic acid, and the like; the alkaryl sulfonates such as the sodium alkyl aryl sulfonates, e.g., sodium isopropyl benzene sulfonate, sodium isopropyl naphthalene sulfonate; and the alkali metal salts of sulfonated dicarboxylic acid esters and amides such as sodium dioctyl sulfosuccinate, sodium N-octadecyl-sulfonsuccinamide, sulfonated or sulfated alkyl phenoxyethoxyethanols having from 1 to 50 oxyethylene units per molecule in which the alkyl group has from 4 to 18 carbon atoms, such as hexyl, n-octyl, t-octyl, lauryl, hexadecyl, and octadecyl, and the like.

Cationic emulsifiers include stearamidopropyldimethyl-betahydroxyethyl ammonium dihydrogen phosphate, stearamidopropyldimethyl-beta-hydroxyethyl ammonium nitrate, stearoguanamine, stearoguanamine ethylene oxide reaction products, octadecylamine salts of octadecyl carbamic acid and octadecyl guanamine salts of octadecyl carbamic acid reacted with ethylene oxide, octadecylamine tetraethylene glycol, rosin amine ethylene oxide reaction products, and the like. Also included are undecylimidazoline and reaction products with ethylene oxide and propylene oxide; oleylaminodiethylamine hydrochloride; condensation products of fatty acids and degraded proteins; monostearylethylenediamine trimethylammonium sulfate; alkyl benzene imidazolines, cetyl pyridinium bromide, octadecyl pyridinium sulfate or chloride, octadecylmethyl pyridinium acetate; laurylureaethylene oxide; methyl sulfate of dimethyl octadecyl sulfonium; condensates of halohydrins and amines, polyamines and ammonia; alkyl phosphonium compounds, alkyl phosphonium ethylene oxide condensates, rosin amines condensed with ethylene oxide and propylene oxide; cetyl dimethylbenzyl ammonium chloride, distearyl dimethyl ammonium chloride, stearyl dimethylbenzyl ammonium chloride, n-alkyl dimethylbenzyl ammonium chloride, methyl dodecylbenzyl trimethyl ammonium chloride, methyl dodecyl xylene bis(trimethylammonium chloride), cetyl trimethyl ammonium bromide, and the like.

Amphoteric emulsifiers include the sodium salt of N-coco beta aminopropionate, N-coco beta aminopropionic acid, disodium N-lauryl beta-iminodipropionate, dicarboxylic coconut derivative diethanolamine salt, dicarboxylic palmitic derivative sodium salt, C-cetyl betaine, and N-lauryl betaine.

Fluorine containing surfactants of all types are useful, whether ionic or nonionic. Among the anionic types may be mentioned ammonium perfluoroalkyl sulfonates, potassium perfluoroalkyl sulfonates, potassium fluorinated alkyl carboxylates, and ammonium perfluoro alkyl carboxylates. The fluorinated alkyl esters are examples of nonionic types. The foregoing and other fluorine containing surfactants are commercially available, such as surfactants FC-93, FC-95, FC-128, FC-143, FC-430 and F-431 sold by 3M Company.

Naturally occurring emulsifiers or derivatives thereof are also useful. These include the alginates, cellulose derivatives such as methyl cellulose and carboxymethyl cellulose, water soluble gums such as gum arabic and gum tragacanth, the phospholipids (such as lecithin), and the sterols.

Preferred emulsifying agents are the nonionic emulsifiers, Pluronic (trademark) F-68 and Pluronic F-108, and yolk-phospholipid. The Pluronic emulsifiers are polyoxyethylenes and polyoxpropylenes available from Wyandotte-BASF. Typically, the emulsifier (whether nonionic or ionic) is used in an amount up to about 10 wt. % of the total emulsion composition, or up to about 5 wt. % based on the water used to form the emulsion. Greater amounts can be used if desired. The emulsifiers can be used singly or in combination provided they are ionically compatible.

The amounts and proportions of inert, organic, gas transporting liquid water and emulsifying agent used to form the emulsion and gel can vary over a wide range. Generally, the amounts of each ingredient will be such as to form an emulsion and can be readily determined by one skilled in the art without undue experimentation. However, the preferred concentration of the organic liquid is in the range of from about 1 wt. % to about 70 wt. %, more preferably from about 10 to about 50 wt. % on total composition.

In another aspect of the present invention, the gel can be treated to contain more oxygen than would otherwise result. One such technique is to contact the organic liquid prior to combining it with the other material, with additional oxygen. For example, the organic liquid prior to emulsification may be subjected to an environment of 100% oxygen at a pressure equal to or greater than 760 mm Hg. Alternatively, the resulting gel is subjected to an environment of 100% oxygen which may be at a pressure equal to or greater than 760 mm Hg.

The mixture of organic liquid, water and emulsifying agent is emulsified by any conventional means of agitation, for example, by hand stirring, aeration, propeller agitation, turbine agitation, colloid milling, homogenizing, high-frequency or ultrasonic oscillation (sonication), and the like. In most instances emulsification is effective at ambient temperature. However, with some of the foregoing agitation means, excess heat may be generated during the formation of the emulsion and/or gel and will be removed by known means, e.g., cooling jacket. The amount of mechanical energy input from the various agitation means can vary substantially depending on, for example, the amount of material being worked and the equipment used.

In the second step of preparing the gels of the invention, the emulsion is concentration to form a gel phase and a liquid phase. High speed centrifugation ("ultracentrifugation"), for example at about 10,000 to 20,000 rpm, is effective for this purpose, the selection of speed being dependent on the proportion of organic liquid in the emulsion (the less organic liquid, the greater the speed). The result is a clear, supernatant liquid and a paste-like solid (the gel phase) which falls to the bottom of the vessel.

In the third step, the gel phase and liquid phase are separated, as by settling, evaporation, decantation, or filtration such as pressure filtration or vacuum filtration. Separation may be partial or complete, depending on what further processing is required. For example, if it is desired to admix other adjuvants with the gel at this point, such as antimicrobial agents, pharmaceuticals, hermectants, perfumes, colorants, or other additives known to the cosmetic chemist, it may be preferable to leave some of the liquid in contact with the gel. On the other hand, if immediate packaging or use is contemplated, complete separation of the liquid may be desirable.

The foregoing description of the second and third steps is a sequential concentration and separation process. These steps may also be effected simultaneously by microfiltration (also known as "ultrafiltration"). However, microfiltration is effective only for emulsions of relatively coarse particle size, of the order of more than 1 micron, since most commercial microfiltration membranes have an apparent pore diameter of 1 micron down to about 0.002 micron. Thus, if the emulsion particles are very fine, they may pass through the microfiltration membrane and will not be separated. Since many of the emulsions of this invention have particle sizes in the range of from about 0.1 to about 10 microns, microfiltration is a practical method of simultaneously concentrating the emulsion to form a gel and separating the gel from the resulting supernatant liquid phase. Suitable microfiltration membranes include products available from the Millipore Company and Amicon Corporation as described, for example, in U.S. Pat. Nos. 3,615,024 and 3,856,569.

Generally, when it is desired to simultaneously form the gel and separate the gel from the aqueous phase, a coarse emulsion particle size is desirable. Such emulsions are formed when the ingredients are utilized in the following proportions:

______________________________________inert organic liquid               10-50    vol. %surfactant          2-25     wt. %water               25-90    wt. %______________________________________

The proportions may vary outside these ranges depending on the character of the inert organic liquid and surfactant.

Pressure or vacuum filtering or decantation can be used in conjunction with microfiltration, if desired. Pressure filtration is preferred over vacuum filtration due to a tendency to foaming during vacuum filtration.

If desired, an antimicrobial material such as an antibacterial agent and/or an antibiotic agent can be incorporated into the gels of the invention. The antibacterial agent counteracts aerobic bacteria which might multiply in the presence of the gel since the gel can contain large amounts of oxygen. Examples of suitable antibacterial agents include quinoline carboxylic acids, nitrofurans and sulfonamides. Suitable agents are those which do not affect the gel or ones not affected by the gel. Examples of suitable antibiotic agents include aminoglyosides, ansamacrolides, chloramphenicol and its analogues, lincosaminides, macrolides, nurleosides, oligosaccharides, peptides, phenazines, polyenes, polyethers, tetracyclines, and others. The foregoing agents are described in greater detail in Encyclopedia of Chemical Technology, Vol. 2, pages 752-1036 and Vol. 3, pages 7-78, both 3rd Edition. The aforementioned agent can be incorporated into the gel at any step in the preparation thereof, for example, by addition to a liquid ingredient prior to the emulsification (e.g., dissolving in the water), by dispersion in the emulsion during or after emulsification, or by blending with the gel after separation.

The resulting gel can be used as an ointment applied to the skin of higher mammals including humans, for treatment of wounds, bruises or irritations. The gel may also be formed or incorporated into a dressing and the dressing applied to the skin. ¢Dressing" as used herein includes any material suitable for contacting (including a wound) with the gel and maintaining the gel in such contact, such as gauze, bandages, surgical wrappings, and the like. The following examples illustrate several embodiments of the invention, but without intent to limit the scope thereof, except as set forth in the appended claims.

EXAMPLE 1

Four grams (2 cc) of F-tributylamine (perfluorotributylamine) and 18 cc of water containing 5 wt. % of Pluronic F68 emulsifying agent were placed in a test tube. The perfluorocarbon was evenly dispersed in the water by sonication. The test tube containing the milk-like emulsion was then centrifuged at 10,000 rpm for 10 minutes. The result was a clear supernatant liquid and a paste-like solid (gel) at the bottom. The clear liquid was poured from the tube leaving behind the gel. The gel was removed from the tube with a spatula to another container. The gel had the appearance of petroleum jelly and weighed 5 grams.

Ethanol, 5 cc, was added to the gel. Four grams of F-tributylamine, the amount used to form the emulsion initially, separated out as a clear liquid layer from the water-ethanol layer, indicating that the gel contained 80% by weight of fluorocarbon.

The foregoing procedure was repeated, except for the use of ethanol, and the separated gel was kept in a clear, wide-mouth jar. After 75 days no visible change was noted in the physical appearance of the gel, such as separation of the perfluorocarbon from the water, thus indicating that the gel was stable.

EXAMPLE 2

Pluronic F-68 surfactant, 1.35 g., was added to 25.65 g. water. To this aqueous mixture was added 3 cc (6 g.) of F-tributylamine. The resulting composition was sonicated to form an opalescent emulsion of relatively coarse particle size (about 1-10 microns average particle size). The emulsion was filtered under about 25 psig. nitrogen pressure through a Millipore (trademark) microporous membrane of 0.45 micron apparent pore size. A gel formed and remained on the filter. The gel was readily transferrable to a storage container.

EXAMPLE 3l

The preparative technique of Example 2 was repeated in all essential respects except for substitution of F-trimethylbicyclononane for the F-tributylamine. A gel of substantially equivalent appearance was obtained.

EXAMPLE 4

Substantially as described in Example 1, an emulsion was prepared by forming a solution containing 23.5 cc of water and 5 wt. % PLURONIC F-68 emulsifier, adding 2.5 cc of General Electric Silicone Oil SF 96-50, and sonicating to a milky-white emulsion. The silicone oil has a viscosity of 50 c St , a specific gravity of 0.963, a flash point of 460° F. and a pour point of -67° F. The emulsion was then centrifuged at 14000 rpm for 20 minutes, whereupon a white, pasty gel separated. The separated fluid was then decanted from the gel.

Claims (1)

I claim:
1. A method for preparing a gel, comprising:
(a) admixing an inert, water-immiscible organic liquid having gas transporting capability, water, and an emulsifying agent under condition of agitation and in proportions effective to form an emulsion; and
(b) concentrating the emulsion to form a gel phase and a liquid phase.
US06777798 1980-11-17 1985-09-19 Preparation of a gel having gas transporting capability Expired - Fee Related US4879062A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US06313124 US4569784A (en) 1980-11-17 1981-10-20 Preparation of a gel having gas transporting capability
US06777798 US4879062A (en) 1981-10-20 1985-09-19 Preparation of a gel having gas transporting capability

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06777798 US4879062A (en) 1981-10-20 1985-09-19 Preparation of a gel having gas transporting capability

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06313124 Continuation US4569784A (en) 1980-11-17 1981-10-20 Preparation of a gel having gas transporting capability

Publications (1)

Publication Number Publication Date
US4879062A true US4879062A (en) 1989-11-07

Family

ID=26978698

Family Applications (1)

Application Number Title Priority Date Filing Date
US06777798 Expired - Fee Related US4879062A (en) 1980-11-17 1985-09-19 Preparation of a gel having gas transporting capability

Country Status (1)

Country Link
US (1) US4879062A (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071644A (en) * 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US5077033A (en) * 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
US5124151A (en) * 1990-08-07 1992-06-23 Mediventures Inc. Drug delivery by injection with thermo-irreversible gels
US5126141A (en) * 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5183589A (en) * 1989-03-31 1993-02-02 Ausimont S.R.L. Stable emulsions of perfluoropolyethers
US5185099A (en) * 1988-04-20 1993-02-09 Institut National De Recherche Chimique Appliquee Visco-elastic, isotropic materials based on water, fluorinate sufactants and fluorinated oils, process for their preparation, and their use in various fields, such as optics, pharmacology and electrodynamics
US5350359A (en) * 1992-07-16 1994-09-27 Temple University Of The Commonwealth System Of Higher Education Control, treatment and/or diagnosis of physiological conditions with degassed perfluorocarbon liquid
US5851544A (en) * 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
US6140285A (en) * 1998-07-30 2000-10-31 Charlotte-Mecklenburg Hospital Authority Use of dioctyl sulfosuccinate salts for cleaning petroleum contaminated surfaces
US6346272B1 (en) 1990-08-07 2002-02-12 Mdv Technologies, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US6436425B1 (en) 1988-11-16 2002-08-20 Mdv Technologies, Inc. Method and non-gelling composition for inhibiting post-surgical adhesions
US20060193878A1 (en) * 2002-09-24 2006-08-31 Therox, Inc. Method of Preparing Gas Delivering Perfluorocarbon Emulsions With Non-Fluorinated Surfactants
US20070282434A1 (en) * 2006-05-30 2007-12-06 Yunbing Wang Copolymer-bioceramic composite implantable medical devices
US20090169630A1 (en) * 2006-05-15 2009-07-02 Kevin Ward Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications
US20090202617A1 (en) * 2008-02-13 2009-08-13 Ward Kevin R Gas based wound and tissue therapeutics
US20100144861A1 (en) * 2008-11-25 2010-06-10 Gary Huvard Perfluorocarbon gel formulations
US20100144597A1 (en) * 2008-12-10 2010-06-10 Ward Kevin R Novel combinatorial approaches to enhancing oxygen transport to tissues
US20110039944A1 (en) * 2008-01-22 2011-02-17 Capelli Christopher C Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US20110086923A1 (en) * 2009-07-28 2011-04-14 Thompson Deborah P Method to increase oxygen in male and female sexual organs through the topical use of perfluorocarbons
US20110159078A1 (en) * 2008-01-22 2011-06-30 Vapogenix, Inc Volatile Anesthetic Compositions and Methods of Use
US20110230566A1 (en) * 2010-03-19 2011-09-22 Maria Isabel Tamargo Perfluorocarbon eye cream formulations
US8513309B2 (en) 2010-10-01 2013-08-20 Oxygen Biotherapeutics, Inc. Perfluorocarbons for use in treating pruritus
US9744142B2 (en) 2009-05-05 2017-08-29 Board Of Regents, The University Of Texas Systems Formulations of volatile anesthetics and methods of use for reducing inflammation

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3277013A (en) * 1963-10-03 1966-10-04 G H Packwood Mfg Company Waterless skin cleaner and process for producing the same
US3778381A (en) * 1972-04-24 1973-12-11 Allied Chem Fluorocarbon microemulsions
US3823091A (en) * 1971-05-19 1974-07-09 Green Cross Corp Stable emulsion of fluorocarbon particles
US3850753A (en) * 1972-03-23 1974-11-26 Tanabe Seiyaku Co Cultivation of aerobic microorganisms
US3911138A (en) * 1973-02-26 1975-10-07 Children S Hospital Inc Of Cin Artificial blood and method for supporting oxygen transport in animals
US3993581A (en) * 1973-10-05 1976-11-23 The Green Cross Corporation Process for preparing stable oxygen transferable emulsion
US4105798A (en) * 1976-07-19 1978-08-08 Sun Ventures, Inc. Perfluoro polycyclic compounds for use as synthetic blood and perfusion media
US4166006A (en) * 1977-11-10 1979-08-28 Corning Glass Works Means for stimulating microbial growth
US4299728A (en) * 1980-07-21 1981-11-10 Instrumentation Laboratory Inc. Blood gas control
US4366169A (en) * 1979-06-25 1982-12-28 Sun Tech, Inc. Use of perfluorocarbons as wound treatment
US4569784A (en) * 1980-11-17 1986-02-11 Adamantech, Inc. Preparation of a gel having gas transporting capability

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3277013A (en) * 1963-10-03 1966-10-04 G H Packwood Mfg Company Waterless skin cleaner and process for producing the same
US3823091A (en) * 1971-05-19 1974-07-09 Green Cross Corp Stable emulsion of fluorocarbon particles
US3850753A (en) * 1972-03-23 1974-11-26 Tanabe Seiyaku Co Cultivation of aerobic microorganisms
US3778381A (en) * 1972-04-24 1973-12-11 Allied Chem Fluorocarbon microemulsions
US3911138A (en) * 1973-02-26 1975-10-07 Children S Hospital Inc Of Cin Artificial blood and method for supporting oxygen transport in animals
US3911138B1 (en) * 1973-02-26 1996-10-29 Childrens Hosp Medical Center Artificial blood and method for supporting oxygen transport in animals
US3993581A (en) * 1973-10-05 1976-11-23 The Green Cross Corporation Process for preparing stable oxygen transferable emulsion
US4105798A (en) * 1976-07-19 1978-08-08 Sun Ventures, Inc. Perfluoro polycyclic compounds for use as synthetic blood and perfusion media
US4166006A (en) * 1977-11-10 1979-08-28 Corning Glass Works Means for stimulating microbial growth
US4366169A (en) * 1979-06-25 1982-12-28 Sun Tech, Inc. Use of perfluorocarbons as wound treatment
US4299728A (en) * 1980-07-21 1981-11-10 Instrumentation Laboratory Inc. Blood gas control
US4569784A (en) * 1980-11-17 1986-02-11 Adamantech, Inc. Preparation of a gel having gas transporting capability

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185099A (en) * 1988-04-20 1993-02-09 Institut National De Recherche Chimique Appliquee Visco-elastic, isotropic materials based on water, fluorinate sufactants and fluorinated oils, process for their preparation, and their use in various fields, such as optics, pharmacology and electrodynamics
US5126141A (en) * 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
US6436425B1 (en) 1988-11-16 2002-08-20 Mdv Technologies, Inc. Method and non-gelling composition for inhibiting post-surgical adhesions
US5562911A (en) * 1989-03-31 1996-10-08 Ausimont Spa Stable emulsions of perfluoropolyethers
US5330681A (en) * 1989-03-31 1994-07-19 Ausimont S.R.L. Stable emulsions of perfluoropolyethers
US5183589A (en) * 1989-03-31 1993-02-02 Ausimont S.R.L. Stable emulsions of perfluoropolyethers
US5277911A (en) * 1990-08-07 1994-01-11 Mediventures, Inc. Ablatable mask of polyoxyalkylene polymer and ionic polysaccharide gel for laser reprofiling of the cornea
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5124151A (en) * 1990-08-07 1992-06-23 Mediventures Inc. Drug delivery by injection with thermo-irreversible gels
US6346272B1 (en) 1990-08-07 2002-02-12 Mdv Technologies, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5077033A (en) * 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
US5071644A (en) * 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US5350359A (en) * 1992-07-16 1994-09-27 Temple University Of The Commonwealth System Of Higher Education Control, treatment and/or diagnosis of physiological conditions with degassed perfluorocarbon liquid
US5851544A (en) * 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
US6140285A (en) * 1998-07-30 2000-10-31 Charlotte-Mecklenburg Hospital Authority Use of dioctyl sulfosuccinate salts for cleaning petroleum contaminated surfaces
US7357937B2 (en) 2002-09-24 2008-04-15 Therox, Inc. Perfluorocarbon emulsions with non-fluorinated surfactants
US20060193878A1 (en) * 2002-09-24 2006-08-31 Therox, Inc. Method of Preparing Gas Delivering Perfluorocarbon Emulsions With Non-Fluorinated Surfactants
US7468191B2 (en) 2002-09-24 2008-12-23 Therox, Inc. Method of preparing gas delivering perfluorocarbon emulsions with non-fluorinated surfactants
US20060193799A1 (en) * 2002-09-24 2006-08-31 Therox, Inc. Method of Making Perfluorocarbon Emulsions With Non-Fluorinated Surfactants
US20090169630A1 (en) * 2006-05-15 2009-07-02 Kevin Ward Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications
US20070282434A1 (en) * 2006-05-30 2007-12-06 Yunbing Wang Copolymer-bioceramic composite implantable medical devices
US20110039944A1 (en) * 2008-01-22 2011-02-17 Capelli Christopher C Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US9675544B2 (en) 2008-01-22 2017-06-13 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US9566251B2 (en) 2008-01-22 2017-02-14 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
US20110159078A1 (en) * 2008-01-22 2011-06-30 Vapogenix, Inc Volatile Anesthetic Compositions and Methods of Use
US20090202617A1 (en) * 2008-02-13 2009-08-13 Ward Kevin R Gas based wound and tissue therapeutics
US8343515B2 (en) 2008-11-25 2013-01-01 Oxygen Biotherapeutics, Inc. Perfluorocarbon gel formulations
US20100144861A1 (en) * 2008-11-25 2010-06-10 Gary Huvard Perfluorocarbon gel formulations
US20100144597A1 (en) * 2008-12-10 2010-06-10 Ward Kevin R Novel combinatorial approaches to enhancing oxygen transport to tissues
US9744142B2 (en) 2009-05-05 2017-08-29 Board Of Regents, The University Of Texas Systems Formulations of volatile anesthetics and methods of use for reducing inflammation
US20110086923A1 (en) * 2009-07-28 2011-04-14 Thompson Deborah P Method to increase oxygen in male and female sexual organs through the topical use of perfluorocarbons
US20110230566A1 (en) * 2010-03-19 2011-09-22 Maria Isabel Tamargo Perfluorocarbon eye cream formulations
US8513309B2 (en) 2010-10-01 2013-08-20 Oxygen Biotherapeutics, Inc. Perfluorocarbons for use in treating pruritus

Similar Documents

Publication Publication Date Title
US4056611A (en) Therapeutic composition
US2558395A (en) Undenatured gelatin hemostatic sponge containing thrombin
US4529605A (en) Bathing oil composition
Yamakoshi et al. Solubilization of fullerenes into water with polyvinylpyrrolidone applicable to biological tests
US4443480A (en) Artificial blood and other gas transport agents
US5676971A (en) Agents for inhibiting adsorption of proteins on the liposome surface
US4707293A (en) Detergent composition
US4942038A (en) Encapsulated humectant
US3981996A (en) Pharmaceutical skin compositions
US4684633A (en) Phospholipid-emulsified prostaglandin composition
US20020090386A1 (en) Skin barrier composition
Krafft et al. Highly fluorinated amphiphiles and colloidal systems, and their applications in the biomedical field. A contribution
US4670185A (en) Aqueous vesicle dispersion having surface charge
US3947573A (en) Opthalmic solution
US4532130A (en) Preparation of synthetic frythrocytes
US6096324A (en) Methods of delivering materials into the skin, and compositions used therein
Putnam The interactions of proteins and synthetic detergents
US4774017A (en) Thickening agent for detergent containing preparations
US4389419A (en) Vitamin encapsulation
Krafft Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical research
US4751241A (en) Pharmaceutical composition of cyclandelate having a high degree of bioavailability
US6224853B1 (en) Aqueous compositions comprising a lipid and a lanolin-derived surfactant, and their use
US5635171A (en) Cosmetic or pharmaceutical composition in the form of a rigid gel, particularly for containing inclusions therein
US20060251685A1 (en) Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US5389676A (en) Viscous surfactant emulsion compositions

Legal Events

Date Code Title Description
AS Assignment

Owner name: ADAMANTECH, INC., 1501 BLUEBALL AVENUE, LINWOOD, P

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:MOORE, ROBERT E.;REEL/FRAME:004929/0202

Effective date: 19851029

Owner name: ADAMANTECH, INC., A CORP. OF DE, PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MOORE, ROBERT E.;REEL/FRAME:004929/0202

Effective date: 19851029

AS Assignment

Owner name: AFFINITY BIOTECH, INC., GREAT VALLEY CORPORATE CEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST. EFFECTIVE JANUARY 16, 1990;ASSIGNOR:ADAMANTECH, INC.;REEL/FRAME:005262/0286

Effective date: 19900319

Owner name: AFFINITY BIOTECH, INC., A CORP. OF NJ,PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ADAMANTECH, INC.;REEL/FRAME:005262/0286

Effective date: 19900319

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: IBAH, INC., PENNSYLVANIA

Free format text: MERGER;ASSIGNOR:AFFINITY BIOTECH, INC.;REEL/FRAME:007275/0246

Effective date: 19940427

AS Assignment

Owner name: LDS TECHNOLOGIES, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IBAH, INC.;REEL/FRAME:008000/0930

Effective date: 19960612

AS Assignment

Owner name: LDS TECHNOLOGIES, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IBAH, INC.;REEL/FRAME:008022/0823

Effective date: 19960618

AS Assignment

Owner name: ALLIANCE PHARMACEUTICAL CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LDS TECHNOLOGIES, INC.;REEL/FRAME:008231/0995

Effective date: 19960819

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Expired due to failure to pay maintenance fee

Effective date: 20011107